Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896618516> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2896618516 endingPage "375" @default.
- W2896618516 startingPage "371" @default.
- W2896618516 abstract "Background and purpose Rituximab, a chimeric anti‐CD20 monoclonal antibody, has been used in polyneuropathy associated with anti‐myelin‐associated glycoprotein (anti‐MAG) antibody polyneuropathy with controversial results. Herein, two patients with anti‐MAG antibody neuropathy and concurrent chronic lymphocytic leukemia (CLL) are reported, who dramatically responded to obinutuzumab, a novel glycoengineered humanized anti‐CD20 monoclonal antibody. Methods Patient 1 was an 82‐year‐old man with severe demyelinating sensory‐motor neuropathy. He was wheelchair‐bound, with loss of sensation up to the knees. He had a CLL, immunoglobulin M (IgM) lambda monoclonal gammopathy, with anti‐MAG antibodies >70 000 Bühlmann titer units (BTU). Patient 2 was an 84‐year‐old woman with demyelinating neuropathy, paresthesias and gait instability. She had CLL and IgM kappa paraprotein with anti‐MAG antibodies >70 000 BTU. Both patients were treated with obinutuzumab intravenously at 100 mg on day +1, 900 mg +2, then at 1000 mg on days 8 and 15 of cycle 1 and day 1 of cycles 2–6; chlorambucil was given orally at 0.5 mg/kg on days 1 and 15 of cycles 1–6. Results Patient 1 at cycle 6 was able to stand, gait was possible with monolateral support, hypoesthesia and strength improved. M‐protein and IgM level decreased. In patient 2, already after three cycles, the monoclonal component disappeared and there was dramatic improvement of symptoms and gait normalization. At the end of therapy anti‐MAG antibody titer decreased to 5462 BTU. Neurophysiology also improved. Conclusions In our patients, obinutuzumab was effective as a first‐line treatment of anti‐MAG antibody polyneuropathy. CLL might have had a role in the response to therapy, but the associations might be considered in future trials." @default.
- W2896618516 created "2018-10-26" @default.
- W2896618516 creator A5013236194 @default.
- W2896618516 creator A5022496451 @default.
- W2896618516 creator A5038006814 @default.
- W2896618516 creator A5042091314 @default.
- W2896618516 creator A5074848198 @default.
- W2896618516 date "2018-11-27" @default.
- W2896618516 modified "2023-09-25" @default.
- W2896618516 title "Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy" @default.
- W2896618516 cites W1876001658 @default.
- W2896618516 cites W2053106166 @default.
- W2896618516 cites W2066357502 @default.
- W2896618516 cites W2091057822 @default.
- W2896618516 cites W2147466128 @default.
- W2896618516 cites W2208017095 @default.
- W2896618516 cites W2613337099 @default.
- W2896618516 cites W2783410073 @default.
- W2896618516 cites W2795881860 @default.
- W2896618516 doi "https://doi.org/10.1111/ene.13838" @default.
- W2896618516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30315672" @default.
- W2896618516 hasPublicationYear "2018" @default.
- W2896618516 type Work @default.
- W2896618516 sameAs 2896618516 @default.
- W2896618516 citedByCount "13" @default.
- W2896618516 countsByYear W28966185162019 @default.
- W2896618516 countsByYear W28966185162020 @default.
- W2896618516 countsByYear W28966185162021 @default.
- W2896618516 countsByYear W28966185162022 @default.
- W2896618516 countsByYear W28966185162023 @default.
- W2896618516 crossrefType "journal-article" @default.
- W2896618516 hasAuthorship W2896618516A5013236194 @default.
- W2896618516 hasAuthorship W2896618516A5022496451 @default.
- W2896618516 hasAuthorship W2896618516A5038006814 @default.
- W2896618516 hasAuthorship W2896618516A5042091314 @default.
- W2896618516 hasAuthorship W2896618516A5074848198 @default.
- W2896618516 hasConcept C126322002 @default.
- W2896618516 hasConcept C159654299 @default.
- W2896618516 hasConcept C18031839 @default.
- W2896618516 hasConcept C203014093 @default.
- W2896618516 hasConcept C2775892965 @default.
- W2896618516 hasConcept C2776694085 @default.
- W2896618516 hasConcept C2776755627 @default.
- W2896618516 hasConcept C2777607594 @default.
- W2896618516 hasConcept C2777866208 @default.
- W2896618516 hasConcept C2777938653 @default.
- W2896618516 hasConcept C2778461978 @default.
- W2896618516 hasConcept C2778842783 @default.
- W2896618516 hasConcept C2779263901 @default.
- W2896618516 hasConcept C2780653079 @default.
- W2896618516 hasConcept C71924100 @default.
- W2896618516 hasConcept C90924648 @default.
- W2896618516 hasConceptScore W2896618516C126322002 @default.
- W2896618516 hasConceptScore W2896618516C159654299 @default.
- W2896618516 hasConceptScore W2896618516C18031839 @default.
- W2896618516 hasConceptScore W2896618516C203014093 @default.
- W2896618516 hasConceptScore W2896618516C2775892965 @default.
- W2896618516 hasConceptScore W2896618516C2776694085 @default.
- W2896618516 hasConceptScore W2896618516C2776755627 @default.
- W2896618516 hasConceptScore W2896618516C2777607594 @default.
- W2896618516 hasConceptScore W2896618516C2777866208 @default.
- W2896618516 hasConceptScore W2896618516C2777938653 @default.
- W2896618516 hasConceptScore W2896618516C2778461978 @default.
- W2896618516 hasConceptScore W2896618516C2778842783 @default.
- W2896618516 hasConceptScore W2896618516C2779263901 @default.
- W2896618516 hasConceptScore W2896618516C2780653079 @default.
- W2896618516 hasConceptScore W2896618516C71924100 @default.
- W2896618516 hasConceptScore W2896618516C90924648 @default.
- W2896618516 hasIssue "2" @default.
- W2896618516 hasLocation W28966185161 @default.
- W2896618516 hasLocation W28966185162 @default.
- W2896618516 hasOpenAccess W2896618516 @default.
- W2896618516 hasPrimaryLocation W28966185161 @default.
- W2896618516 hasRelatedWork W1768515905 @default.
- W2896618516 hasRelatedWork W1796006501 @default.
- W2896618516 hasRelatedWork W203548035 @default.
- W2896618516 hasRelatedWork W2040935430 @default.
- W2896618516 hasRelatedWork W2173371792 @default.
- W2896618516 hasRelatedWork W2606155555 @default.
- W2896618516 hasRelatedWork W2766509541 @default.
- W2896618516 hasRelatedWork W4230048971 @default.
- W2896618516 hasRelatedWork W1924806264 @default.
- W2896618516 hasRelatedWork W2183070500 @default.
- W2896618516 hasVolume "26" @default.
- W2896618516 isParatext "false" @default.
- W2896618516 isRetracted "false" @default.
- W2896618516 magId "2896618516" @default.
- W2896618516 workType "article" @default.